Biomarin Pharmaceutical (BMRN) Operating Margin (2017 - 2025)
Historic Operating Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 6.02%.
- Biomarin Pharmaceutical's Operating Margin fell 212900.0% to 6.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.89%, marking a year-over-year increase of 71800.0%. This contributed to the annual value of 16.97% for FY2024, which is 92900.0% up from last year.
- Per Biomarin Pharmaceutical's latest filing, its Operating Margin stood at 6.02% for Q3 2025, which was down 212900.0% from 33.55% recorded in Q2 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Operating Margin peaked at 33.55% during Q2 2025, and registered a low of 14.65% during Q4 2021.
- For the 5-year period, Biomarin Pharmaceutical's Operating Margin averaged around 8.77%, with its median value being 7.33% (2022).
- In the last 5 years, Biomarin Pharmaceutical's Operating Margin surged by 212800bps in 2022 and then crashed by -212900bps in 2025.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's Operating Margin stood at 14.65% in 2021, then soared by 83bps to 2.43% in 2022, then soared by 273bps to 4.22% in 2023, then skyrocketed by 412bps to 21.6% in 2024, then plummeted by -128bps to 6.02% in 2025.
- Its Operating Margin stands at 6.02% for Q3 2025, versus 33.55% for Q2 2025 and 30.05% for Q1 2025.